SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) — Adaptive Research Inc. (the “Company”), a healthcare…
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical…
Medical cannabis provider aims to accelerate research efforts throughout North America TORONTO, March 16, 2021…
Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or…
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX…
BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant…
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQX: BTTR) (“Better Choice”…
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to…
SAFEbody technology enables precision masking of antibodies for enhanced safety SAN FRANCISCO and SUZHOU, China,…
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab…
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA®…
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic…
Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France and…
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to…
Topline Results Expected in the Second Quarter of 2021 SAN DIEGO, March 16, 2021 (GLOBE…
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Management to host conference call and webcast on March 23rd at 5:00 pm EDT /…
– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set…
Programs receiving funding include those developing company’s proprietary cryopreserved NK and gamma delta T-cell candidates…